Skip to content

Study · Animal study (in vivo) · rat · 2007

2 results

MIF-1 and its peptidomimetic analogs attenuate haloperidol-induced vacuous chewing movements and modulate apomorphine-induced rotational behavior in 6-hydroxydopamine-lesioned rats.

Castellano JM, Batrynchuk J, Dolbeare K, Verma V, Mann A, Skoblenick KJ, Johnson RL, Mishra RK

Peptides1 Aug 2007Cited by 7 (Europe PMC)

PMID17766011 (opens in a new tab)DOI10.1016/j.peptides.2007.07.026 (opens in a new tab)PepBankPUB-17766011
Publisher pagePubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

2 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Activity measurement

    In rat dopaminergic behavioral assays, native PLG had significantly lower potency than analogs A and B.

    In plain wordsIn rats, native PLG had lower potency than the two tested analogs.

    Peptide
    MIF-1 (Pro-Leu-Gly-NH2)
    Outcome
    DecreasePotency in dopaminergic behavior assays
    Study

    ratn: not reported in source

    6-OHDA lesion and haloperidol-induced behavioral models
    Comparator
    peptidomimetic analogs A and B
    Outcome group
    Receptor activity and mechanism · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    The potency and efficacy of these analogs were significantly greater than their parent compound, PLG.
    1 context sentence
    Summary · context
    were evaluated for their ability to modulate dopaminergic activity by measuring apomorphine-induced rotations in 6-hydroxydopamine (6-OHDA)-lesioned rats, and haloperidol (HP)-induced vacuous chewing movements (VCMs) in rats; animal models of Parkinson's disease (PD) and human tardive dyskinesia (TD), respectively.
  2. 02AnimalAnimal study (in vivo)Activity measurement

    In rat dopaminergic behavioral assays, native PLG had significantly lower efficacy than analogs A and B.

    In plain wordsIn rats, native PLG had lower efficacy than the two tested analogs.

    Peptide
    MIF-1 (Pro-Leu-Gly-NH2)
    Outcome
    DecreaseEfficacy in dopaminergic behavior assays
    Study

    ratn: not reported in source

    6-OHDA lesion and haloperidol-induced behavioral models
    Comparator
    peptidomimetic analogs A and B
    Outcome group
    Receptor activity and mechanism · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    The potency and efficacy of these analogs were significantly greater than their parent compound, PLG.
    1 context sentence
    Summary · context
    were evaluated for their ability to modulate dopaminergic activity by measuring apomorphine-induced rotations in 6-hydroxydopamine (6-OHDA)-lesioned rats, and haloperidol (HP)-induced vacuous chewing movements (VCMs) in rats; animal models of Parkinson's disease (PD) and human tardive dyskinesia (TD), respectively.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.